Double-Blind, Randomized, Active-Controlled Comparison of the Immunogenicity and Safety of Flublok Quadrivalent Versus IIV4 in Healthy, Medically Stable Adults 18-49 Years of Age
Phase of Trial: Phase III
Latest Information Update: 09 Sep 2017
At a glance
- Drugs Influenza virus RIV4 vaccine-(FluBlok Quadrivalent) (Primary) ; Influenza virus vaccine
- Indications Influenza virus infections
- Focus Pharmacodynamics; Registrational
- Sponsors Protein Sciences Corporation
- 09 Sep 2017 Results published in the Journal of Infectious Diseases.
- 26 Oct 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 09 Dec 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.